drugset / Trial / NCT01359228

Rifaximin Treatment of Papulopustular Rosacea

NCT01359228

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to determine the effects of rifaximin on skin symptoms in patients with rosacea by double-blinded, placebo-controlled, crossover study.

Timeline

Start
2013-04
Primary completion
2014-06
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifaximin Other / unclassified 550 mg

Indications